@entity12232 ( XXXX ) for the treatment of non-small cell lung cancer.

@entity1 @entity4153 @entity5 @entity2 @entity15152 @entity12232
INTRODUCTION: Epigenetic aberrations play an important role in lung carcinogenesis. Chromatin deacetylation is a fundamental mechanism of gene silencing. @entity15152 ( @entity15152 ) inhibitors are an emerging class of antineoplastic agents that enable the accessibility of DNA to transcription factors, therefore promoting gene expression. @entity12232 is a selective @entity15152 inhibitor that has shown anti-neoplastic activity and tolerability in hematologic and solid @entity5 , including @entity2 . Areas covered: This article summarizes the pharmacokinetics, pharmacodynamics, mechanisms of action, safety, tolerability, pre-clinical studies and clinical trials of the @entity15152 inhibitor @entity12232 , as a novel promissory agent for the treatment of NSCLC. Expert opinion: The field of targeted therapy has @entity2 . However, even now with the current FDA-approved agents, < 15% of @entity1 benefit from these interventions and we are still far from curing @entity2 . New targets are needed. Either in combination with cytotoxic drugs, epigenetic therapy or other molecular targeted drugs, @entity12232 represents a new potential agent for the treatment of @entity4153 . However, the preliminary safety and efficacy results from several clinical trials still need to be validated in large Phase III trials.
